Research analysts covering Prenetics Global.
Recent press releases and 8-K filings for PRE.
Prenetics Global outlines strategic shift to IM8 Health and strong growth projections
PRE
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Prenetics Global (PRE) is undergoing a strategic shift to focus primarily on its IM8 Health brand, having divested most other business units and planning to divest its $70 million investment in Insighta.
- IM8 Health, co-founded with David Beckham and launched in late 2024, achieved $60 million in full-year 2025 revenue and projects $180 million-$200 million for full-year 2026, demonstrating rapid growth with $120 million in Annual Recurring Revenue (ARR) in under 12 months.
- The company reports a strong financial position with approximately $110 million in pure cash and 510 Bitcoin on its balance sheet, with zero debt as of January 2026.
- IM8 Health boasts strong unit economics, including an average order value (AOV) above $200 and a customer acquisition cost payback period of less than three months.
Jan 21, 2026, 1:30 PM
Prenetics Global Reports Strong IM8 Growth and Positive Financial Outlook
PRE
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Prenetics (PRE) is transforming into an IM8-focused consumer brand, having divested other business units and being in the process of divesting its stake in Insighta.
- The company reported FY 2025 estimated revenue of $80 million - $100 million and forecasts FY 2026 revenue of $180 million - $200 million, with IM8 achieving a $120 million Annual Recurring Revenue (ARR).
- Prenetics maintains a strong balance sheet with approximately $110 million in pure cash and 510 Bitcoin, with zero debt. The estimated total asset value, including a $70 million investment in Insighta and a $380 million valuation for the IM8 business, is approximately $560 million.
- IM8, co-founded with David Beckham, has demonstrated rapid growth, becoming the fastest supplement brand to hit $120 million ARR. It operates on a 100% direct-to-consumer model with a 60% gross margin and 80% customer retention on subscriptions.
Jan 21, 2026, 1:30 PM
Prenetics Global Achieves 2025 Revenue Estimates and Forecasts Significant 2026 Growth
PRE
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Prenetics Global (PRE) achieved its estimated $80 million-$100 million full-year revenue for 2025 and forecasts significant growth with $180 million-$200 million in full-year revenue for 2026.
- The IM8 brand, co-founded with David Beckham, has reached $120 million ARR in less than 12 months, with a 60% gross margin and 80% of customers on monthly or three-month subscriptions.
- The company maintains a strong balance sheet with over $110 million in cash and 510 Bitcoin, zero debt, and is in the process of divesting its $70 million stake in Insighta.
- IM8's average order value has increased to above $200, and its customer acquisition payback period is now lower than three months, indicating strong unit economics.
Jan 21, 2026, 1:30 PM
Prenetics Global Limited Completes Sale of Europa Business
PRE
M&A
Guidance Update
- Prenetics Global Limited completed the sale of its Europa Sports Partners 3PL distribution business for up to $13 million in an all-stock transaction, effective January 1, 2026.
- This strategic divestiture is intended to sharpen the company's focus on its IM8 brand and is expected to improve operating margins beginning in Q2 2026, as the Europa business incurred approximately $6 million in operating losses in fiscal year 2025.
- For the full year 2026, the company projects total revenues from IM8 to be between $180 and $200 million.
- Prenetics maintains a strong balance sheet with approximately $118 million in total liquidity, including over $70 million in cash and cash equivalents and 510 BTC, with zero debt.
Jan 6, 2026, 1:03 PM
Prenetics Provides Update on Voluntary Warrant Exchange Program
PRE
- Prenetics Global Limited announced an update on its voluntary warrant exchange program, with participation reaching 86.7% as of January 5, 2026, an increase from approximately 83.4% previously.
- The company has entered into exchange agreements covering 4,720,832 of the 5,445,284 aggregate Class A and Class B warrants issued in the October 2025 financing round.
- These warrants are expected to be exchanged for approximately 2.36 million Class C warrants.
- Following the exchange, the total number of outstanding Class A, Class B, and Class C warrants is expected to be approximately 3.08 million, representing a 43.3% reduction from the warrants issued in the October 2025 financing round.
- The anticipated dilutive impact on the company's total outstanding shares is projected to decrease from approximately 32.3% to 18.3%.
Jan 5, 2026, 1:20 PM
Prenetics Updates Capital Allocation Strategy, Ceases Bitcoin Purchases to Focus on IM8
PRE
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Prenetics Global Limited announced on December 30, 2025, an update to its capital allocation strategy, ceasing Bitcoin purchases to exclusively focus on its IM8 brand.
- The company stopped daily Bitcoin purchasing on December 4, 2025, and will not acquire additional Bitcoin, but will retain its existing 510 BTC as a treasury reserve asset.
- This strategic realignment follows the rapid success of IM8, which achieved over $100 million in annualized recurring revenue (ARR) within 11 months of launch.
- Prenetics projects IM8's FY 2026 revenue to reach $180 - $200 million.
- The company's capital allocation will now be directed exclusively towards IM8's growth, operations, and strategic expansion, supported by a strong balance sheet with over $70 million in cash and cash equivalents and zero debt.
Dec 30, 2025, 1:22 PM
Prenetics Global Limited Enters Warrant Exchange Agreements
PRE
- Prenetics Global Limited entered into warrant exchange agreements on December 23, 2025, with holders representing approximately 83.4% of its outstanding Class A and Class B warrants.
- The exchange aims to simplify the Company's capital structure and materially reduce potential future dilution.
- Holders exchanged two (2) existing Class A or Class B warrants for one (1) new Class C warrant.
- The existing Class A warrants had an exercise price of $24.12 and Class B warrants had an exercise price of $32.16. The new Class C warrants have an exercise price of $18.00 per Ordinary Share and a two-year term.
- This exchange is expected to reduce the total number of outstanding warrants by approximately 42.0%, from 5,445,284 to approximately 3.18 million in aggregate.
Dec 23, 2025, 4:21 PM
Prenetics Global Outlines Strategic Pivot to IM8 Brand and Financial Outlook
PRE
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Prenetics (ticker PRE) is strategically pivoting its focus to its IM8 consumer healthcare brand, co-founded with David Beckham, and is in the process of divesting other business units including Europa, CircleDNA, and its 35% stake in Insighta valued at $70 million.
- The company projects full-year 2025 revenues of $90-$100 million and $180-$200 million for 2026, with IM8 alone expected to achieve $60 million in revenue in 2025 and $180-$200 million in 2026.
- IM8, launched in December 2024, achieved a $100 million Annual Recurring Revenue (ARR) run rate in 11 months and reached $10 million in monthly revenue in November 2025, making it the fastest-growing supplement brand in the industry.
- Prenetics maintains a strong balance sheet with approximately $70 million in cash and $47 million in Bitcoin holdings (510 BTC), totaling $117 million in cash and BTC as of December 2025. The company also has zero debt.
- The company is implementing a Bitcoin treasury strategy, buying one Bitcoin daily to dollar-cost average, viewing it as a long-term hedge against inflation, and aims for a 30%-35% Bitcoin to cash ratio.
Dec 10, 2025, 3:00 PM
Prenetics Global Outlines Strategic Focus on IM8 and Strong Growth Projections
PRE
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Prenetics Global is divesting non-core assets to concentrate on its rapidly growing consumer healthcare brand, IM8, which is projected to achieve $180-$200 million in revenue in 2026.
- IM8, co-founded with David Beckham, reached a $100 million ARR in 11 months and recorded $10 million in monthly revenue as of November 2025.
- The company maintains a strong financial position with approximately $70 million in cash and 510 BTC (totaling approximately $117 million in cash and BTC holdings) and zero debt.
- Prenetics reported decreasing quarterly losses, from $6.5 million in Q1 to $2.1 million in Q3, while maintaining significant growth.
Dec 10, 2025, 3:00 PM
Prenetics Global Highlights Rapid IM8 Growth and Strategic Divestments
PRE
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Prenetics Global is strategically divesting non-core assets, including Europa, CircleDNA, and its 35% stake in Insighta (valued at $70 million), to concentrate on its rapidly growing consumer healthcare brand, IM8.
- The IM8 brand achieved $100 million in annual recurring revenue (ARR) in 11 months and is projected to generate $180-$200 million in revenue next year.
- The company maintains a strong financial position with approximately $70 million in cash and 510 BTC, totaling about $117 million in cash and Bitcoin holdings, and operates with zero debt.
- Prenetics has shown a trend of decreasing quarterly losses, from $6.5 million in Q1 to $2.1 million in Q3, while continuing its rapid growth trajectory for IM8.
- The company estimates a total net asset value of approximately $560 million, including a conservative $380 million valuation for the IM8 business.
Dec 10, 2025, 3:00 PM
Quarterly earnings call transcripts for Prenetics Global.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more